Prosecution Insights
Last updated: April 19, 2026
Application No. 17/555,220

Irreversible Electroporation Return Electrode and System

Non-Final OA §103
Filed
Dec 17, 2021
Examiner
LANCASTER, LINDSAY REGAN
Art Unit
3794
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
BIOSENSE WEBSTER (ISRAEL) LTD.
OA Round
3 (Non-Final)
56%
Grant Probability
Moderate
3-4
OA Rounds
3y 10m
To Grant
82%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allow Rate
53 granted / 95 resolved
-14.2% vs TC avg
Strong +26% interview lift
Without
With
+26.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
47 currently pending
Career history
142
Total Applications
across all art units

Statute-Specific Performance

§101
3.2%
-36.8% vs TC avg
§103
67.4%
+27.4% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
5.1%
-34.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 95 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Status of the Claims The current office action is made responsive to claims filed 01/06/2026. Acknowledgement is made to the amendment of claims 1, 7-8, 11-12, 16 and 18-19. Acknowledgement is made to the cancellation of claims 3-4, 9-10, 14-15, 17, and 20. Any claims listed above as cancelled have sufficiently overcome any rejections set forth in any of the prior office actions. Claims 1-2, 5-8, 11-13, 16, and 18-19 are pending. A complete action on the merits appears below. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-2, 5, 7-8, 11-13, 16, and 18 are rejected under 35 U.S.C. 103 as being unpatentable over Selig (US 20110202055 A1) in view of Neal (US 20180132922 A1) and Lee (US 20070049919 A1). Regarding claim 1, Selig teaches a system (Fig. 1; HF generator system 30) for controlling delivery of current from a generator comprising a generator ([0050]), the system comprising: a body surface electrode (Fig. 1 & 3; neutral electrode 10) comprising: two electrodes (Fig. 1; first electrode section 11 and second electrode section 11’) for coupling with a unipolar pulse delivery electrode (Fig. 1 & 3; monopolar instrument 20) in communication with the generator ([0050]), the two electrodes in communication with skin of a patient ([0050]), the two electrodes communicating with the generator to return current to the generator ([0003]), and the two electrodes spaced apart a predetermined distance from each other along the body surface electrode ([0052]) to measure electrical impedance between the two electrodes, the measured electrical impedance corresponding to a first temperature ([0054]); and the body surface electrode being configured to output temperature data based on the measured electrical impedance corresponding to the first temperature ([0051], [0054]); and a processor (Fig. 2; control device 36) in communication with the at least one temperature measuring device, the processor programmed to: receive the temperature data from the body surface electrode ([0024]- [0025]); analyze the received temperature data to determine whether (i) a measured second temperature, by at least one thermocouple, at least meets a threshold temperature or (ii) the measured electrical impedance, between the two electrodes and corresponding to the first temperature, exceeds a threshold impedance that corresponds to the threshold temperature ([0051] discusses the temperature of the neutral electrode being determined by a measurement device and the and the system responding when the temperature reaches a temperature which could lead to burns, [0054] discusses the measurement device as measuring the impedance based on the current applied to the two electrode sections and determine the current based on this impedance); and output a signal to terminate pulse delivery from the generator to the unipolar delivery electrode, if the threshold temperature is met ([0043], [0051]). However, Selig fails to teach the energy being delivered from the generator as being irreversible electroporation (IRE) pulses from an IRE generator. Neal teaches a system for ablating tissue in a treatment region of a patient’s body comprising a single-pole electrode probe for insertion into the treatment region, an external surface electrode for placement outside the patient’s body to complete the circuit with the single-pole electrode, and a device for delivering electric energy to the single-pole electrode and the skin-surface electrode to the treatment region (Abstract, [0038]). Neal further teaches the device for delivering energy to the electrode system for treating the tissue as being a generator for delivering high-frequency irreversible electroporation pulses ([0038]). Therefore, it would have been obvious to a person having ordinary skill in the art before the effective filing date to have substituted the generator for applying energy to tissue, as is taught by Selig with the generator for applying energy to tissue as is taught by Neal, to produce the predictable result of applying energy to tissue, as it has been held that the substitution of one known element for another according to known methods to yield predictable results is an obvious modification. MPEP 2141(III). Selig further fails to teach the system comprising at least one temperature measuring device configured to measure a second temperature, the at least one temperature measuring device comprising at least one thermocouple and the body surface electrode being configured to output temperature data based on the measured second temperature. Lee teaches an ablation system having multiple ground pads which is controlled so as to reduce the risk of patient skin burns (Abstract). Lee further teaches the use of both measured impedances at the ground pads and temperature measurements ([0050]), which are received by thermocouples ([0047]), to control the device to reduce the risk patient burns ([0009], [0045]). Therefore it would have been obvious to a person having ordinary skill in the art before the effective filing date to have incorporated the thermocouple for measuring temperature to control the ablation device in addition to impedance measurements controlling the ablation device, so as to reduce patient burn risks, as is taught by Lee, into the ablation device which is controlled by impedance measurements as is taught by Selig, to produce the predictable result of controlling an ablation device using known measurements to reduce patient burn risk, as is taught by Lee, as it has been held that the incorporation and/or combination of prior art elements according to known methods to yield predictable results is an obvious modification. MPEP 2141(III). Regarding claim 2, Selig teaches the system of claim 1, wherein the body surface electrode includes a patch for adhering to the skin of the patient ([0052]). Regarding claim 5, Selig teaches the system of claim 1, wherein the processor is programmed to transmit the signal to the generator to terminate the delivery of the current ([0051]). In accordance with the above provided rejection of claim 1, Neal further teaches the delivery of current as being in the form of pulses. Regarding claim 7, Selig teaches the system of claim 6, wherein the generator, the switch, the unipolar delivery electrode, and the two electrodes of the body surface electrode form an electrical circuit ([0003], [0050]- [0051]). In accordance with the above provided rejection of claim 1, Neal further teaches the unipolar delivery electrode as being a unipolar IRE delivery electrode. Regarding claim 8, Selig teaches the system of claim 1, wherein the generator, the unipolar delivery electrode, and the two electrodes of the body surface electrode form an electrical circuit ([0003], [0050]- [0051]). In accordance with the above provided rejection of claim 1, Neal further teaches the unipolar delivery electrode as being a unipolar IRE delivery electrode. Regarding claims 11-13, 16, and 18, the method steps are the same as described as the steps the system is configured to perform and therefore taught in the same way as seen in claims 1-2, 5, and 7-8. Claims 6 and 19 are rejected under 35 U.S.C. 103 as being unpatentable over Selig (US 20110202055 A1) in view of Neal (US 20180132922 A1) and Lee (US 20070049919 A1) further in view of Cohen (US 20130310829 A1). Regarding claim 6, Selig teaches the system of claim 1, additionally comprising: a switch for moving between a first position, where pulses are moving between the generator and the unipolar delivery electrode, and a second position, where the pulses are prohibited from moving between the generator and the unipolar delivery electrode ([0051] discusses the use of a switch for the purpose of stopping the output of energy to the monopolar instrument), and the processor is programmed to transmit the signal to the switch to move to the second position, to terminate the delivery of the current ([0051] teaches the control device as controlling the generator, the generator being the element which is switched off). However, Selig is silent on the position of the switch as being specifically intermediate the generator and the unipolar delivery electrode. Cohen teaches an ablation catheter system for delivering treatment to a patient (Abstract). The ablation catheter system having a kill switch mechanism which immediately and abruptly terminates delivery of ablation treatment or therapy (Abstract). Cohen further teaches the kill switch as being located between the generator and the ablation catheter and switching from a normally closed position to an open position in order to terminate the delivery of energy from the generator to the ablation catheter ([0059], [0196]). Therefore it would have been obvious to a person having ordinary skill in the art before the effective filing date to have incorporated the teachings of the switch which terminates the delivery of ablation therapy as being located between the generator and the catheter, as is taught by Cohen, into the system having a switch which is turned off to stop ablating tissue as is taught by Selig, to produce the predictable result of terminating the delivery of ablation energy to tissue by a switch, as is taught by Cohen, as it has been held that the incorporation and/or combination of prior art elements according to known methods to yield predictable results is an obvious modification. MPEP 2141(III). In accordance with the above provided rejection of claim 1, Neal further teaches the unipolar delivery electrode as being a unipolar IRE delivery electrode. Regarding claim 19, the method steps are the same as described as the steps the system is configured to perform and therefore taught in the same way as seen in claim 6. Response to Arguments Applicant’s arguments with respect to the claims have been considered but are moot because the amendments have necessitated new grounds of rejection. Specifically, applicant’s arguments of the limitations that art not taught by the Dunning in view of Neal reference are moot in view of the new rejections under Selig, Neal and Lee. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to LINDSAY REGAN LANCASTER whose telephone number is (571)272-7259. The examiner can normally be reached Monday-Thursday 8-4 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Linda Dvorak can be reached on 571-272-4764. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LINDA C DVORAK/Primary Examiner, Art Unit 3794 /L.R.L./Examiner, Art Unit 3794
Read full office action

Prosecution Timeline

Dec 17, 2021
Application Filed
Sep 25, 2024
Non-Final Rejection — §103
Dec 27, 2024
Response Filed
Mar 04, 2025
Final Rejection — §103
Sep 15, 2025
Response after Non-Final Action
Jan 06, 2026
Request for Continued Examination
Feb 19, 2026
Response after Non-Final Action
Mar 07, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594112
Cryogenic Applicator
2y 5m to grant Granted Apr 07, 2026
Patent 12594118
SYSTEMS, DEVICES, AND ASSOCIATED METHODS FOR NEUROMODULATION WITH ENHANCED NERVE TARGETING
2y 5m to grant Granted Apr 07, 2026
Patent 12575878
MAPPING AND ABLATION CATHETER WITH MULTIPLE LOOP SEGMENTS
2y 5m to grant Granted Mar 17, 2026
Patent 12558264
SYSTEMS FOR INCISING TISSUE
2y 5m to grant Granted Feb 24, 2026
Patent 12544121
SYSTEMS AND METHODS FOR PROSTATE TREATMENT
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
56%
Grant Probability
82%
With Interview (+26.2%)
3y 10m
Median Time to Grant
High
PTA Risk
Based on 95 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month